BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands NAMs Strategy to Advance BiTAC(R) Therapies
VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant preclinical testing methods across its antibody-based cancer drug development programs, aiming to improve the clinical relevance of research findings while reducing animal testing. The company is implementing New Approach Methodologies (“NAMs”), including three-dimensional tumor spheroid models and patient-derived tumor models, in support of its BiTAC(R) T-cell engagers, antibody-drug conjugates and bispecific antibody-drug conjugates. VERAXA reported that its lead BiTAC T-cell engager demonstrated selective, potent T-cell-mediated tumor-cell killing across 10 patient-derived non-small cell lung cancer models, while relevant controls showed minimal activity. The ex vivo study required approximately 10 mice, compared…
